Business
Industry Leaders Select Resverlogix's RVX-208
Among top 10 most promising drugs TSX Exchange Symbol: RVX CALGARY, July 9 /CNW/ - Resverlogix Co...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nAmong top 10 most promising drugs\n\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, July 9 /CNW/ - Resverlogix Corp's ("Resverlogix" or the\n"Company") (TSX:RVX) novel lead ApoA-I drug candidate, RVX-208 has been\nselected as one of the top 10 most promising cardiovascular disease (CVD)\ndrugs available for strategic partnering by an independent committee assembled\nby Windhover Information, a leading provider of business information products\nand services to senior executives in the pharmaceutical, biotechnology, and\nmedical device industries.\n\n\n"We are honored to be part of this select group of top ten most promising\ninnovative drugs," stated Donald McCaffrey, President and CEO of Resverlogix.\n"It again validates RVX-208 and our entire NexVas(TM) PR franchise as an\nimportant new small molecule drug for the largest market with unmet needs,\natherosclerosis and cardiovascular diseases. We are moving towards our next\nimportant milestone, Phase 1b/2a, later this fall and continue to measure\nsafety, tolerability and key reverse cholesterol transport (RCT) markers such\nas ApoA-I, pre-beta HDL, HDL and cholesterol efflux."\n\n\nThe selection committee was led by Marc Wortman, PhD, contributing writer\nto Windhover's IN VIVO and Start Up publications, and Michael Rice, Senior\nConsultant, and Ed Saltzman, President of Defined Health, a leading business\ndevelopment strategy consulting firm. Drawing on the analytic resources of\nthese organizations, the group evaluated hundreds of compounds currently in\ndevelopment for the treatment of cardiovascular disease prior to selecting\nRVX-208 among the top ten most attractive drug available for partnering.\n\n\n"Selected companies have been screened using a strict set of judging\ncriteria for the Top 10 award, and represent what our committee considered the\nmost attractive cardiovascular opportunities the industry has to offer,"\nstated Roger Longman, Managing Director of Windhover Information. "Winners\nhave met strict criteria including: unmet medical need, market potential,\ndiversity of indications, strong science, multi-level partnering opportunities\n(biotech and pharma), potential for new opportunities beyond initial\nindications, history of the molecule and drug and be a strong company."\n\n\n"To have a hig...